News

Press Release
RepliCel Announces Record Year in Patents Granted
Patents granted in the United States, China, South Korea, Japan, Israel and New Zealand for...
Press Release
RepliCel Announces Appointment of Leading Sports Medicine Expert as Orthopedics Clinical Advisor (Japan)
Professor Tsukasa Kumai, member of the Japan’s Olympic Committee Medical and Scientific Staff, will lead...
Press Release
RepliCel Closes Second Tranche of Strategic Investment Commitment
MainPointe Pharmaceuticals Completes Largest Scheduled Share Purchases per Investment AgreementVANCOUVER, BC, CANADA – 29 April...
Events
RepliCel Presents its Technology Development and Commercialization Plans for Japan at Kanagawa Regenerative Medicine Industry Conference
Kanagawa Regeneration and Cell Medical Industry Network Organizers Invite RepliCel to Participate in Foreign Company...
Press Release
RepliCel Closes First Tranche of Strategic Investment Commitment
MainPointe Pharmaceuticals Completes Initial Share Purchase per Investment AgreementVANCOUVER, BC, CANADA – 10 February 2021...
Press Release
RepliCel CEO Provides Corporate Update
Targets for 2021 include dermal injector commercial launch, new partnerships, new innovation initiatives, and launch...
Press Release
RepliCel and MainPointe Pharmaceuticals Sign Strategic Investment and Collaboration Agreement
RepliCel and MainPointe Pharmaceuticals Sign Strategic Investment and Collaboration AgreementMainPointe Deal Positions RepliCel for entry...
Press Release
RepliCel Announces Adoption of Advance Notice Bylaw and Shareholder Rights Plan as well as Transitions in its Board of Directors
VANCOUVER, BC, CANADA – December 11, 2020 – RepliCel Life Sciences Inc. (OTCPK: REPCF) (TSXV: RP)...
Press Release
RepliCel Announces Details of its Annual General Meeting
VANCOUVER, BC, CANADA – December 1, 2020 – RepliCel Life Sciences Inc. (OTCPK: REPCF) (TSXV: RP) (FRA:P6P2)...
Press Release
RepliCel Announces a Binding Term Sheet For Strategic Investment and U.S. Partnership
Transaction represents RepliCel's entrance into the US market Investment terms minimize dilution and puts RepliCel...
Press Release
RepliCel Q3 2020 Management Update
Japan, China, and Dermal Injector Programs Progress to MilestonesVANCOUVER, BC, CANADA – 14 September 2020 –...
Press Release
Replicel Announces Extension to Private Placement
VANCOUVER, BC – August 10, 2020 – Replicel Life Sciences Inc. (the "Company" or "Replicel") announces that...
Press Release
RepliCel Life Sciences Announces the Closing of the First Tranche Private Placement and Amendments to Debt Settlement
VANCOUVER, BC – July 15, 2020 - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) (FRA:...
Press Release
Replicel Postpones Filing of Annual Financial Statements and MD&A Due to COVID-19 Related Delays
VANCOUVER, BC – 22 April, 2020 – Replicel Life Sciences Inc. ("Company" or "Replicel") has...
Press Release
Publication of Clinical Data Confirms RepliCel’s Treatment for Androgenic Alopecia Effective in Men and Women
A randomized, placebo-controlled, double-blinded clinical study in Japan testing a one-time injection of RCH-01 in...
Press Release
Japan’s Patent Office Issues RepliCel Two New Patents for its Regenerative Medicine Technologies
Timely patent-grants support next steps in RepliCel’s First-in-Japan strategyVANCOUVER, BC, CANADA – 10 March 2020 – RepliCel Life...
Press Release
Japan's Regulatory Agency, PMDA, Clears RepliCel Life Sciences to Proceed to Final Consultation for Tendon and Skin Cell Therapy Products
RepliCel completes the second of three formal consultation reviews with Japan's Pharmaceuticals and Medical Devices Agency in...
Press Release
Production of Dermal Injectors Delayed by China Work Stoppage Affecting Critical Component
Production of Dermal Injectors Delayed by China Work Stoppage Affecting Critical ComponentInitial run of commercial-grade...
Press Release
Commercial-Grade Replicel Injectors RepliCel in Production
Commercial-Grade Replicel Injectors RepliCel in ProductionInitial units will be dedicated to the functional and clinical testing needed...
Press Release
RepliCel Announces its Incoming Board of Directors
RepliCel Announces its Incoming Board of DirectorsSuccessful Annual General Meeting Confirms Director Slate for 2020VANCOUVER,...

DISCLAIMER:
The information in these press releases is historical in nature, has not been updated, and is current only to the date indicated in the particular press release. This information may no longer be accurate and therefore you should not rely on the information contained in these press releases. To the extent permitted by law, RepliCel Life Sciences Inc. and its employees, agents and consultants exclude all liability for any loss or damage arising from the use of, or reliance on, any such information, whether or not caused by any negligent act or omission.

THIRD PARTY CONTENT
Please note that any opinion, estimates or forecasts made by the authors of these statements are theirs alone and do not represent opinions, forecasts or predictions of RepliCel Life Sciences Inc. or its management. RepliCel Life Sciences Inc. does not, by its reference or distribution of these links imply its endorsement of, or concurrence with, such information, conclusions or recommendations.